CAN-BIND-17 Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Summary
Major depressive disorder (MDD) is a common, life-disrupting and highly recurrent illness. Unfortunately, 30–40% of patients do not respond to currently available interventions. The research study we are conducting hopes to shorten the path from diagnosing a person with MDD to starting them on a right, or 'personalized', treatment plan. To achieve this we examine brain scans, clinical assessments and blood samples to gain a better understanding of depression and how best to treat it. we are.
To do so, we are seeking to recruit participants who either have major depressive disorder (MDD) and are currently experiencing symptoms of depression.
We are also recruiting healthy comparison participants.
Eligibility
Eligible ages: 18 to 65
Accepts healthy participants: Yes
Inclusion criteria:
Inclusion criteria:
Patients with MDD must
1. Meet have a confirmed diagnosis of major depressive disorder
2. Agree to stop any medication before starting the study and being prescribed the study medication
3. Be fluent in English to understand the interviews and questionnaires.
Healthy Comparison Participants must
1. Not have a history of any psychiatric disorder
2. Not have any significant physical or medical condition (e.g., arthritis, fibromyalgia)
3. Be fluent in English to understand the interviews and questionnaires.
Exclusion criteria:
Exclusionary criteria include:
1. Bipolar Disorder
2. Substance dependence/abuse in the past 6 months
3. Pregnancy or breastfeeding
4. Neurological disorders or head trauma
5. Having previously failed escitalopram or have shown an intolerance to escitalopram.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Stefanie Hassel Phone: 403-210-7445 Email: canbind@ucalgary.ca
Principal investigator:
Valerie Taylor
Clinical trial:
Yes
REB-ID:
REB21-1606
External links